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Abstract: In this study, the protective effects of cysteamine, putrescine, and the combination of cysteamine and putrescine were
investigated in mice with fibrosarcoma induced with 3-methylcholanthrene (3-MC). A total of 135 adult male albino mice (Mus
musculus), 2–3 months old and weighing 20 ± 2.0 g, were used in this study. All groups (each consisting of 15 mice) were fed ad libitum.
The experimental groups were Group 1 (drinking water), Group 2 (0.2 mL sesame oil s.c.), Group 3 (1 mg 3-MC/0.2 mL sesame oil),
Group 4 (0.1% cysteamine), Group 5 (0.1% putrescine), Group 6 (0.1% cysteamine + putrescine), Group 7 (1 mg 3-MC/0.2 sesame
oil + 0.1% cysteamine), Group 8 (1 mg 3-MC/0.2 mL sesame oil + 0.1% putrescine), and Group 9 (1 mg 3-MC/0.2 mL sesame oil +
0.1% cysteamine + 0.1% putrescine). Experimental groups were given cysteamine and/or putrescine mixed with drinking water right
after being injected with 3-MC subcutaneously. After 7 months, the mice were euthanized by means of cervical dislocation and were
evaluated morphologically and histopathologically. The results showed that the number of tumors of 3-MC-induced fibrosarcoma were
reduced from the highest to the lowest by cysteamine, cysteamine + putrescine, and putrescine, respectively.
Key words: Fibrosarcoma, 3-methylcholanthrene, cysteamine, putrescine

1. Introduction
Although many studies have been done on cancer, it is
still a disease that is very difficult to treat. Healthy cells
as well as cancer cells suffer from the effects of the drugs
given in treatment. This increases the toxicity of antitumor
drugs (1). In order to achieve effective treatment, it is very
important to discover drugs that have a very specific effect.
Chemical substances are one of the major causes
of tumors. Substances that enter the body exhibit
carcinogenic effects either directly (primary carcinogens)
or through their metabolites (secondary carcinogens).
Carcinogenic substances show their effect by reacting with
DNA. Compounds of methyl or epoxide can bind to DNA
and cause cancer. If the tumor cell that develops is not
eliminated by the immune system, it grows and turns into
cancer (1–3).
Animals like mice, guinea pigs, cats, and dogs
are frequently used in cancer research. One of the
* Correspondence: dincererdag@hotmail.com

primary chemical substances used to induce cancer is
3-methylcholanthrene (3-MC), an unsaturated polycyclic
aromatic hydrocarbon (PAH). 3-MC is effective at
causing DNA methylation. It initiates cancer by causing
a breakdown in the DNA molecule. 3-MC administered
subcutaneously to mice at a dose of 1 mg has been reported
to cause fibrosarcoma at a rate of 70%–80% within 1–2
months (4–7). At a dose of 200 mg/kg, 3-MC causes cancer
when administered orally to laboratory animals (4–6).
Studies have also determined that 3-MC has genotoxic and
immunotoxic effects (8,9).
Epoxide metabolites of 3-MC are highly predisposed
to reacting with DNA, resulting in a carcinogenic
effect. The metabolites induce oxidation, methylation,
or hydroxylation in DNA. These reactions explain the
mechanism of 3-MC’s carcinogenic effect (1,2,4,5,7).
The effect of 3-MC can be observed in monooxygenase,
which is an aryl hydrocarbon receptor. In particular, the
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induction that occurs in monooxygenases that carry flavin
causes the speed of the metabolism to increase (10).
3-MC is highly soluble in fat. It spreads well
throughout the body and easily passes through natural
barriers. It undergoes oxidation and conjugation in the
liver and other organs. It is eliminated through bile and
enters enterohepatic circulation. These pharmacokinetic
characteristics strengthen 3-MC’s carcinogenic effect
(1,4,11). PAH easily spreads through tissues and passes
through the placenta, giving it the potential to cause
cancer in the fetus (8).
Biogenic amines like cysteamine and putrescine form
through decarboxylation of amino acids in the body.
Cysteine, which plays a role in the synthesis of glutathione
and polypeptides in the immune system, undergoes
decarboxylation in the body and is converted into
thioethanolamine, which is also called cysteamine. Since
cysteine plays a role in the conjugation of xenobiotics,
the balance between cysteine and cysteamine is very
important. Cysteamine plays a role in energy production.
It enters the structure of coenzyme A (cysteamine + betaalanine + pantoic acid + adenosine, in turn). It binds to
acetic acid, both serving as a buffer and contributing to
energy production by transporting it to mitochondria
(1,4,5,12,13). Cysteamine is used in the treatment of
cystinosis (15 mg/kg) (14,15). Vecsei et al. (13) and Wilmer
et al. (15) reported that cysteine reduces the synthesis of
somatostatin. This means that cysteamine has the potential
for use in growth deficiency. Studies that have been done
claim that it is effective against fibrosarcoma (4,5).
Putrescine is a diaminobutane that forms through the
decarboxylation of ornithine. It is a foul-smelling product
that develops in meat and canned animal food (1,4,5). It
is thought that putrescine plays a role in the growth and
differentiation of cells. It can be considered to be a storage
location for amine in the body (16,17). It has been claimed
that it can cause cell growth because it stores amine, but
that nitrous oxide derivatives synthesized from amine can
cause damage to cells. It has been shown that putrescine
is found in plants and that some of its analogues can
induce apoptosis. It has been determined that it has an
antiproliferative effect because of its role in the oxidative
system (18). For this reason, it is thought that putrescine
may be effective for the treatment of tumors. Furthermore,
it should be noted that ornithine decarboxylase enzyme
inhibitors reduce the risk of colon cancer (16).
It can be claimed that, due to the functional groups they
carry, cysteamine and putrescine can suppress both energy
metabolism and the proliferation rate of cells. Findings
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obtained in some studies confirm this idea (4,5). The
relationships of cysteamine and putrescine to structures
like coenzyme A (CoA), flavin adenine dinucleotide
(FAD), and nicotinamide adenine dinucleotide (NAD),
as well as the relationship of cysteamine and glutathione,
lead to the possibility that they could have an effect on
proliferation.
The goal of this study was to investigate the effects
of cysteamine, putrescine, and the combination of
cysteamine and putrescine on fibrosarcoma induced in
mice with 3-MC.
2. Materials and methods
This research was conducted after obtaining permission
from the local ethics committee for animal experiments
at Kafkas University (KAÜ-HADYEK 13.04.2012/04).
A total of 135 male albino Mus musculus mice aged 2–3
months and weighing 20 ± 2.0 g were used in the research.
The mice were separated into 9 groups of 15 animals each.
All groups were fed ad libitum with standard diet and
water intake. The feed was obtained from the Bayramoğlu
feed factory in Erzurum; cysteamine (CAS: 156-57-0) was
obtained from Fluka, putrescine (P7505) was obtained
from Sigma, and 3-MC (CAS: 56-49-5) was obtained from
Supelco. 3-MC was prepared with sesame oil at a dose of
1 mg/0.2 mL, while separate 0.1% solutions of cysteamine
and putrescine were prepared with drinking water for a
maximum of a 3-day supply. The solutions were given to
the mice with drinking water ad libitum. Sesame oil and
3-MC were injected in the dorsal thoracic region of the
mice (4,6).
Group 1 was kept as a control group. Group 2 was
subcutaneously injected with 0.2 mL of sesame oil, and
Group 3 was subcutaneously injected with 0.2 mL of the
3-MC solution. Group 4 was administered 0.1% cysteamine,
Group 5 was administered 0.1% putrescine, and Group 6
was administered a mixture of 0.1% cysteamine and 0.1%
putrescine for the duration of the experiment. Group
7 was subcutaneously injected with 0.2 mL of the 3-MC
solution as well as 0.1% cysteamine via drinking water on
the same day for the duration of the experiment. Group
8 was subcutaneously injected with 0.2 mL of the 3-MC
solution and was also given 0.1% putrescine via drinking
water on the same day for the duration of the experiment.
Group 9 was subcutaneously injected with 0.2 mL of the
3-MC solution and was also given 0.1% cysteamine and
0.1% putrescine solutions via drinking water on the same
day for the duration of the experiment.
The animals were checked every 12 h and monitored
for 7 months. At the end of that period, the animals
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were euthanized with cervical dislocation. The dead
animals were weighed and their tissue was subjected to
morphological and histopathological analyses (19). The
sizes and weights of the tumors were measured. Samples
from tissue and fibrosarcoma masses were fixed in a
formaldehyde-alcohol solution and then embedded in
paraffin blocks, from which 6-µm-thick sections were
obtained. The sections were stained with hematoxylin and
eosin for analysis. Minitab 12.1 was used for statistical
evaluation of the tumor data (20).
3. Results
A morphological examination of the mice revealed that
no lesions were observed at the injection sites in Groups
1, 2, 4, 5, and 6, while hair loss, dermatitis, and irritation
were observed in the location where 3-MC was injected in
Groups 3, 7, 8, and 9. Table 1 shows the data for animals
that died, survived, and developed tumors during the
experiment.
No tumors were observed in the mice in Groups 1, 2,
4, 5, and 6, but 11 tumors developed in Group 3 (73.3%),
7 tumors developed in Group 7 (46.6%), 10 tumors
developed in Group 8 (66.6%), and 8 tumors developed in
Group 9 (53.3%). Figures 1 and 2 show a mouse in Group
3 that developed a tumor and the dissected fibrosarcoma.
The fibrosarcomas were microscopically verified. Figure 3
shows the microscopic findings for a mouse that developed
a tumor (Group 3).
Mean weights for the mice were 28.5 g in Group 1, 27.8
g in Group 2, 27.6 g in Group 4, 29.5 g in Group 5, and
28.9 g in Group 6. The weight of the mice and the number,

weight, and size of the tumors were measured; these data
are presented in Table 2. When the results were statistically
evaluated with the chi-square test, no significant difference
was found between the groups with regard to the mouse
and tumor weights or the number of tumors (P ≤ 0.05).
4. Discussion
Many studies have been done to develop new drugs
that have specificity and can be used in the diagnosis,
treatment, and prevention of cancer. The types of animals
and the length of the experiment in such studies vary.
Mice are generally monitored for their lifetime, while rats
and other animals are monitored for 2 years. Sözmen et
al. (6) administered 3-MC to cause fibrosarcoma in mice
and monitored the animals for 6.5 months. In another
study on mice, Doğan et al. (4,5) waited 4–12 months for
fibrosarcoma to develop in the mice. In the present study,
the animals were monitored for 7 months. 3-MC is widely
used to cause cancer for experimental purposes (4–7,9,21).
As a PAH, 3-MC causes cancer within 2–4 weeks when
administered via oral, intraperitoneal, or subcutaneous
routes at doses of 40–200 mg/kg (4–6,21). Tumors have
been obtained by subcutaneously administering 3-MC to
mice at a dose of 1 mg (4–6).
The effect of 3-MC in the body varies depending on
the animal species, individual susceptibility, and the
conditions of the experiment. For this reasons, 3-MC
causes fibrosarcoma to develop in mice at varying
rates (approximately 50%–75%). In a study conducted
by Doğan et al. (4), the authors reported that tumors

Table 1. Data for animals in the groups that survived and developed tumors.
Group

N

Total number of
animals with tumors

Number of animals with
tumors living 7 months later

Number of healthy animals
living 7 months later

Group 1 (control)

15

-

-

13

Group 2 (SO)

15

-

-

14

Group 3 (3-MC)

15

11

5*

2*

Group 4 (C)

15

-

-

10

Group 5 (P)

15

-

-

12

Group 6 (C + P)

15

-

-

11

Group 7 (3-MC + C)

15

7

5*

3*

Group 8 (3-MC + P)

15

10

7*

3*

Group 9 (3-MC + C + P)

15

8

5*

3*

SO: Sesame oil, C: cysteamine, P: putrescine. *: The difference between groups was not significant (P ≤ 0.05).
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Figure 1. A mouse with fibrosarcoma belonging to Group 3.

Figure 2. A resected fibrosarcoma belonging to Group 3.

Figure 3. Microscopic view of the fibrosarcoma resected from a
mouse belonging to Group 3, 200×.
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developed at a rate of 66.6% when 3-MC was administered
subcutaneously at a dose of 1 mg. In a different study
conducted by Doğan et al. (5), fibrosarcoma was identified
at a rate of 73.3% when 3-MC was administered to mice at
a dose of 1 mg. In the present study, tumors also developed
at a rate of 73.3% using the same method. The tumors were
histopathologically verified. The relationship between
the dimensions and weight of tumors was determined
to be statistically insignificant. No metastatic loci were
observed in animals with fibrosarcoma that underwent
necropsy. This is not surprising, since it is known that
fibrosarcomas do not often cause metastasis. However, it
has been reported that after administering 3-MC to mice
subcutaneously at a dose of 1 mg, metastasis was observed
in the liver, lungs, and kidneys (4,5,21).
Because cysteamine functions in the biosynthesis of
CoA, it plays an important role in the tricarboxylic acid
cycle (TCA). This enzyme provides a form of cysteine
storage for the body. Cysteine that is in storage cannot be
used for the synthesis of glutathione. This situation can
suppress the detoxification of certain chemical substances,
thus increasing their toxicity. When an organism is given
cysteamine, the levels of free cysteamine and glutathione
increase. Upon administration, cysteamine forms CoA by
binding to adenosine compounds such as NAD and FAD,
which play a role in energy metabolism. As a result, it
can hinder cell proliferation because energy metabolism
is negatively affected. For this reason, cysteamine can
suppress the effects of carcinogenic agents and can also
prevent cells from multiplying. This hypothesis has been
supported by many studies. Cysteamine has been found to
reduce the incidence of fibrosarcoma induced with 3-MC
in mice (4,5). Some studies report that cysteamine has an
antimutagenic effect (22). It has also been claimed that it
has an antiproliferative effect (23,24). This effect has been
demonstrated in erythroblastic leukemia. Its induction
of apoptosis has been attributed to the fact that it forms
a complex with nitrous oxide (NO) in the cytochrome
oxidase enzyme. N-acetylcysteine, a compound of cysteine,
inhibits proliferation in cancer caused by 3-MC (25). It
has been shown that cysteamine prevents genotoxicity
by binding with hydroxylated bases that are carcinogenic
(22). Pantetheinase hydrolyzes acetyl-CoA, which stores
cysteamine in the body, and releases pantetonic acid and
cysteamine. Cysteamine, on the other hand, transforms
into cysteine and enters the glutathione structure, thus
playing a role in the detoxification of xenobiotics (26).
Because cysteamine is part of the structure of CoA, it
is a necessary substance for producing energy in the
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Table 2. Animal weights and tumor count, weight, and dimensions according to group.

No

G3

G7

G8

G9

AW

TW

TD

AW

TW

TD

AW

TW

TD

AW

TW

TD

1

27.6

6

2 × 2.5 × 2

27.6

-

-

26.8

7.1

3×2×2

26.2

6.2

3 × 2.5 × 2

2

30.1

5

2 × 2.5 × 2

31.5

-

-

30.4

6

2 × 2.5 × 2

28.2

3

33.5

-

-

27.2

8

3×3×2

25.5

4.4

2×2×1

26

5.2

4

27.8

6

3×2×2

24.8

-

-

30.4

5.1

2.5 × 2. × 2

26.3

-

5

31.2

-

-

30.2

3.3

2×1×1

27.2

6

3×2×2

29.5

6.5

3×2×2

6

27.7

5.6

2 × 2 × 1.5

27.5

-

-

29

-

28.1

-

-

7

26.6

6.7

2×2×2

30.5

-

-

30.5

6.1

2 × 2.5 ×

27.1

7

2 × 2.5 × 2

8

25.8

5.8

2 × 2.5 × 1

29.3

7

2×2×2

33.5

5

2
2×3×1

32.4

-

9

27.6

7.1

3×2×2

28.7

-

-

28

-

-

36.2

5

2 × 2 × 1.5

10

32.3

-

-

28.2

6

2×2×2

33.2

-

-

28.5

3.5

2×2×1

11

32.5

6.5

2 × 2.5 × 2

29,4

7

2×3×2

33.3

-

-

25.5

-

-

12

20.7

-

-

30.6

5

2×3×2

29

6.1

2.5 × 2 × 2

30.3

-

-

13

30.6

8.3

2 × 3 × 2.5

26.1

7

3×2×2

28.5

-

-

29.8

5.8

2×2×2

14

27.3

7.9

2.5 × 3 × 2

30.4

-

-

28.4

7

3×2×2

30

7

3 × 2 × 1.5

15

27.1

3.2

1×1×2

30.4

-

-

30

5.6

2 × 2 × 1.5

30.8

-

-

Mean 28.6

6.2

28.8

6.2

29.6

5.8

29

5.8

2×2×2

G: Group, AW: animal weight, TW: tumor weight, TD: tumor dimensions. Weight has been given in grams, and dimensions are in cm.

mitochondria. It has been reported that this is why, in cases
of cystinosis, energy metabolism breaks down and the ATP
level drops (15). In a study conducted by Doğan et al. (4),
the authors reported that fibrosarcoma occurred at a rate
of 73.3% in the group that was administered 3-MC, but
only 53.3% in the group that was given 3-MC immediately
followed by cysteamine. Another study done by Doğan et
al. (5) reported tumors at a rate of 73.3% in the group that
was given 3-MC, 53.3% in the group that was administered
cysteamine 1 month after 3-MC, 40% in the group that was
administered putrescine 1 month after 3-MC, and 46.6%
in the group that was administered cysteamine as well as
putrescine 1 month after 3-MC. The present study found
that tumors developed at a rate of 46.6% in the group that
was given 3-MC and cysteamine at the same time, but
73.3% in the group that was only given 3-MC. The results

of this study do not clearly reveal whether cysteamine
administered at the same time or cysteamine administered
immediately after administration of 3-MC was more
effective in protecting against tumors.
It has been claimed that polyamines influence the
development and differentiation of cells (16,27). It is known
that at low doses, polyamines cause colon cancer to advance
(28). However, it has also been claimed that putrescine
and its analogues induce apoptosis, thus inhibiting cell
multiplication (18,27). It has been determined that high
concentrations of putrescine induce apoptosis and prevent
proliferation (27). This effect of putrescine is attributed to
it increasing NO synthesis, inhibiting redox reactions, or
directly binding to carcinogenic agents (18,29). Ornithine
conjugates with furan metabolites that have a carcinogenic
effect. The fact that ornithine transforms into putrescine
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in the body in the presence of ornithine decarboxylase
may be a factor in the occurrence of this effect of ornithine
(29). These findings strengthen the hypothesis that
putrescine may act by binding to carcinogenic agents. Its
relationship to coenzyme A and TCA also leads to the
conclusion that it has an effect on energy metabolism.
It converts alpha-ketoglutaric acid into glutamine via
glutamate. It can also be claimed that putrescine binds to
acetic acid and blocks energy metabolism, thus leading to
an anticarcinogenic effect. This hypothesis is supported
by the fact that putrescine is excreted in the urine in the
form of products conjugated with acetic acid (5). The
study done by Doğan et al. (5) reported tumors at a rate
of 73.3% in the group that was given 3-MC, 53.3% in
the group that was administered cysteamine 1 month
after 3-MC, 40% in the group that was administered
putrescine 1 month after 3-MC, and 46.6% in the group
that was administered cysteamine as well as putrescine 1
month after administering 3-MC. The study showed that
administering putrescine alone provided better protection
than administering a combination of cysteamine and
putrescine. The present study identified tumors in mice at
a rate of 73.3% in the group that was given 3-MC, 46.6% in
the group that was given cysteamine, 66.6% in the group
that was given putrescine, and 53.3% in the group that was
given cysteamine and putrescine together with 3-MC. The
study shows that the best protection against fibrosarcoma
is provided by cysteamine, followed by the combination of
cysteamine and putrescine, and lastly by putrescine alone.
The finding that cysteamine and putrescine reduce the
incidence of tumors concurs with the other studies, but the
percentages of the results were different. It is notable that
the differences between the results of the experiments are
not statistically significant.
The protective effect of cysteamine may be due to the
conjugation it has with other substances as well as the fact
that it indirectly plays a role in the formation of chelate
and glutathione. Furthermore, biogenic amines convert
the alpha-ketoglutaric acid used in TCA into glutamine,
potentially disrupting energy metabolism. Administering
cysteamine binds adenosine to coenzyme A (cysteamine
+ beta-alanine + pantoic acid + adenosine). Adenosine
structures like NAD and FAD, which play a role in energy
metabolism, increase the levels of other free bases used in
the synthesis of genetic structures. This may prevent cell
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proliferation. Putrescine combines with the adenosine
base, binding it in the form of CoA (it may bind as
putrescine + beta-alanine + pantoic acid + adenosine
or putrescine + pantoic acid + adenosine). In the end, it
suppresses cell proliferation like cysteamine. CoA binds
one acetic acid, while a putrescine compound binds
two acetic acids. Aliphatic amines undergo acetylation
in the body and are eliminated in the form of acetyl
conjugates (1,30). It has been reported that putrescine is
eliminated as a conjugate of acetic acid (30). Consequently,
putrescine can be expected to provide more protection
than cysteamine when taken together with carcinogenic
substances. The relationships between biogenic amines
and various compounds can be depicted as follows:
Adenosine 	
  
ATP 	
  
NAD 	
  
FAD 	
  
CoA 	
  
genetic bases.
It is apparent that when administration of putrescine
is started 1 month after the administration of 3-MC, it
affords better protection than putrescine given at the same
time as 3-MC. Furthermore, it was found that cysteamine
provided better protection in the group in which it was
administered immediately after 3-MC, while putrescine
provided better protection in the group in which it was
started 1 month after 3-MC. This leads us to the conclusion
that these results are due to the fact that putrescine
prevents energy metabolism (since it conjugates with
acetyl). In contrast, it can be claimed that with cysteamine,
these effects originate more from the role it plays in the
metabolism of xenobiotics (glutathione). A study by
Doğan et al. (5) claims that cysteamine and putrescine
are comparable when it comes to the formation of CoA.
However, the results obtained in the current study do not
fully support that hypothesis.
In conclusion, although the results were not statistically
significant, it can be said that cysteamine is most effective
in reducing the rate of fibrosarcoma induced in mice
with 3-MC, followed by the combination of cysteamine
and putrescine, and lastly putrescine alone. We are of the
opinion that the views proposed in this study are capable
of providing a different viewpoint on tumor treatment and
the development of new antitumor drugs. In this regard,
it is very important that the findings obtained here be
verified with more comprehensive studies in order to shed
light on those points that are uncertain.
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